The Procter & Gamble Company · PG · FY2026 Q3 · Calendar Q2 2026

PG Q3 FY26: Organic Sales Top 3% Across All Categories, $1B Cost Headwind Looms

P&G delivered a Q3 FY26 beat with EPS of $1.59 versus $1.56 estimated and revenue of $21.24B versus $20.53B estimated, as organic sales grew over 3% across all ten categories and seven regions. However, roughly $1 billion in after-tax cost headwinds from commodity, energy, and logistics pressures linked to Middle East geopolitical disruption are pressing margins. Management maintained FY26 guidance but now expects full-year EPS toward the lower end of the $6.83-$7.09 range. The stock saw a modest +0.92% abnormal return on the report day but drifted approximately 2.5% lower over the subsequent period, suggesting the market tempered its initial reception as the cost-pressure caveat sank in. At $148.66, the stock trades about 7% below the analyst consensus target of $159.75.

Reported Before market openNYSEConsumer Defensive $346.16B market cap
100quality score

Company context

Snapshot as of publication

The Procter & Gamble Company, commonly referred to as P&G, is a global enterprise that supplies a broad spectrum of branded consumer products to markets worldwide. The company's operations are divided into five main business divisions: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers an assortment of hair care products, including conditioners, shampoos, styling aids, and treatments, under popular names like Head & Shoulders, Herbal Essences, Pantene, and Rejoice. It also features antiperspirants, deodorants, personal cleansing solutions, and skin care items from brands such as Olay, Old Spice, Safeguard, Secret, and SK-II. Within the Grooming division, P&G provides a range of shave care products and grooming appliances, prominently featuring brands like Braun, Gillette, and Venus. The Health Care unit encompasses oral hygiene essentials, including toothbrushes, toothpastes, and other dental care products sold under the Crest and Oral-B brand names.…

Earnings scorecard

Reported versus consensus
Reported EPS $1.59 Consensus $2
EPS surprise +1.9% Reported versus consensus
Reported revenue $21.23B Consensus $20.53B
Revenue surprise +3.4% Reported versus consensus

Earnings History

Estimate Beat Miss Match
PG EPS earnings history estimate and actual scatter chart 8 reported fiscal quarters and 4 future estimate-only quarters. Q2 '24 estimate $1.70 Q2 '24 actual $1.84, beat Q3 '24 estimate $1.41 Q3 '24 actual $1.52, beat Q4 '24 estimate $1.37 Q4 '24 actual $1.40, beat Q1 '25 estimate $1.90 Q1 '25 actual $1.93, beat Q4 '25 estimate $1.42 Q4 '25 actual $1.48, beat Q1 '26 estimate $1.90 Q1 '26 actual $1.99, beat Q2 '26 estimate $1.86 Q2 '26 actual $1.88, beat Q3 '26 estimate $1.56 Q3 '26 actual $1.59, beat Q4 '26 estimate $1.43 Q1 '27 estimate $1.93 Q2 '27 estimate $1.88 Q3 '27 estimate $1.64

Analyst Consensus ?

ConsensusBuy50 ratings
Bullish2652.0%
Neutral2346.0%
Bearish12.0%

1 unmapped firm rating excluded from the percentages.

Analyst 52W Price Targets

$148.63Previous close
$40Low
$161.03Average
$192High

Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 28, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Barclays Equal Weight Equal WeightMaintainJul 21, 2026
JP Morgan Overweight OverweightMaintainJul 16, 2026
B of A Securities Buy BuyMaintainJul 10, 2026
Wells Fargo Overweight OverweightMaintainApr 27, 2026
UBS Buy BuyMaintainApr 27, 2026
TD Cowen Hold HoldMaintainApr 27, 2026
Evercore ISI Group In Line In LineMaintainApr 27, 2026
Piper Sandler Neutral NeutralMaintainApr 8, 2026
Deutsche Bank Hold HoldMaintainMar 30, 2026
Jefferies Buy HoldUpgradeDec 17, 2025
Freedom Broker Hold HoldMaintainOct 29, 2025
Raymond James Outperform OutperformMaintainOct 20, 2025
BNP Paribas Outperform OutperformMaintainAug 15, 2025
Truist Securities Buy BuyMaintainApr 25, 2025
RBC Capital Outperform Sector PerformUpgradeApr 25, 2025
Morgan Stanley Overweight OverweightMaintainApr 25, 2025
Citigroup Buy BuyMaintainApr 25, 2025
Stifel Hold HoldMaintainJan 23, 2025
DA Davidson Buy BuyMaintainJan 23, 2025
DZ Bank Buy HoldUpgradeAug 29, 2024
Argus Research Buy BuyMaintainApr 25, 2024
Bernstein Market Perform Market PerformMaintainOct 12, 2023
Wolfe Research Outperform OutperformMaintainNov 22, 2022
Credit Suisse Neutral NeutralMaintainNov 15, 2022
Goldman Sachs Neutral BuyDowngradeOct 10, 2022
Independent Research Buy HoldUpgradeJan 22, 2021
Berenberg Hold SellUpgradeJan 24, 2019
Bank of America Buy BuyMaintainJan 8, 2019
Macquarie Outperform OutperformMaintainOct 22, 2018
Atlantic Equities Overweight OverweightMaintainSep 20, 2018
B. Riley FBR Neutral BuyDowngradeMay 5, 2018
Stifel Nicolaus Hold HoldMaintainApr 20, 2018
Argus Hold BuyDowngradeApr 20, 2018
B. Riley Securities Neutral BuyDowngradeMar 6, 2017
SunTrust Robinson Humphrey Hold BuyDowngradeDec 22, 2016
CLSA Outperform OutperformMaintainOct 26, 2016
Argus Capital Buy HoldUpgradeOct 12, 2016
Johnson Rice Buy AccumulateMaintainAug 26, 2016
Sterne Agee CRT Buy NeutralUpgradeFeb 16, 2016
Sterne Agee Buy NeutralUpgradeFeb 16, 2016
GMP Securities Hold HoldMaintainFeb 3, 2016
Hilliard Lyons Long Term Buy NeutralUpgradeJun 4, 2015
Societe Generale Hold BuyDowngradeApr 29, 2015
BTIG Research Neutral NeutralMaintainDec 30, 2014
Canaccord Genuity Hold BuyDowngradeNov 17, 2014
Standpoint Research Hold SellUpgradeJan 31, 2014
Exane BNP Paribas Underperform UnderperformMaintainSep 11, 2013
Oracle Investment Research Hold SellUpgradeMay 24, 2013
Tigress Financial Neutral NeutralMaintainFeb 25, 2013
BMO Capital Outperform OutperformMaintainOct 26, 2012
Bank oferica Buy BuyMaintainFeb 28, 2012
Show less

Named analyst price targets

Upside is calculated against the persisted previous close $148.63. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BarclaysAnalyst unavailable$152$149.14 +2.3%Jul 21, 2026
BernsteinAnalyst unavailable$156$148.32 +5.0%Jun 11, 2026
UBSAnalyst unavailable$172$148.46 +15.7%Apr 27, 2026
Deutsche BankSteve Powers$163$148.63 +9.7%Apr 27, 2026
Evercore ISIRobert Ottenstein$162$148.11 +9.0%Apr 27, 2026
Wells FargoAnalyst unavailable$164$148.11 +10.3%Apr 27, 2026
BarclaysAnalyst unavailable$146$143.86 -1.8%Apr 14, 2026
RBC CapitalAnalyst unavailable$167$146.66 +12.4%Apr 9, 2026
Piper SandlerAnalyst unavailable$142$144.9 -4.5%Apr 8, 2026
Wells FargoAnalyst unavailable$177$160.07 +19.1%Feb 17, 2026
UBSAnalyst unavailable$170$151.06 +14.4%Jan 23, 2026
Wells FargoChris Carey$165$149.93 +11.0%Jan 23, 2026
BarclaysLauren Lieberman$155$144.37 +4.3%Jan 16, 2026
UBSPeter Grom$161$146.54 +8.3%Jan 14, 2026
Piper SandlerAnalyst unavailable$150$139.91 +0.9%Jan 7, 2026
Wells FargoAnalyst unavailable$158$140.04 +6.3%Jan 5, 2026
JefferiesAnalyst unavailable$179$145.21 +20.4%Dec 16, 2025
BarclaysAnalyst unavailable$151$143.45 +1.6%Dec 8, 2025
Morgan StanleyAnalyst unavailable$175$151.46 +17.7%Oct 27, 2025
UBSPeter Grom$176$150.92 +18.4%Oct 8, 2025
BarclaysLauren Lieberman$153$153.65 +2.9%Oct 1, 2025
BarclaysAnalyst unavailable$164$152.88 +10.3%Jul 31, 2025
UBSPeter Grom$180$154.94 +21.1%Jul 30, 2025
Redburn PartnersEdward Lewis$161$159.98 +8.3%May 1, 2025
Morgan StanleyDara Mohsenian$180$160.06 +21.1%Apr 25, 2025
BarclaysLauren Lieberman$159$164.74 +7.0%Jan 23, 2025
JefferiesKaumil Gajrawala$174$175.68 +17.1%Dec 5, 2024
Stifel NicolausMark Astrachan$167$176.28 +12.4%Nov 22, 2024
Truist FinancialBill Chappell$180$169.64 +21.1%Oct 21, 2024
RBC CapitalNik Modi$164$169 +10.3%Oct 21, 2024
D.A. DavidsonLinda Bolton Weiser$160$169.02 +7.6%Oct 21, 2024
Raymond JamesOlivia Tong$190$171.28 +27.8%Oct 21, 2024
D.A. DavidsonLinda Bolton Weiser$159$169.27 +7.0%Oct 9, 2024
Goldman SachsBonnie Herzog$164$168.88 +10.3%Oct 4, 2024
BarclaysLauren Lieberman$163$173.55 +9.7%Sep 30, 2024
Piper SandlerKorinne Wolfmeyer$174$173.77 +17.1%Sep 23, 2024
BNP ParibasKevin Grundy$192$177.02 +29.2%Sep 16, 2024
JefferiesKaumil Gajrawala$175$165.93 +17.7%Jul 24, 2024
Stifel NicolausMark Astrachan$161$167.96 +8.3%Jul 22, 2024
Evercore ISIRobert Ottenstein$183$169.44 +23.1%Jul 18, 2024
Deutsche BankSteve Powers$176$168.53 +18.4%Jul 17, 2024
BNP ParibasKevin Grundy$187$168.26 +25.8%Jun 24, 2024
Argus ResearchChris Graja$185$162.88 +24.5%Apr 25, 2024
BarclaysLauren Lieberman$170$160.54 +14.4%Apr 23, 2024
BernsteinAlexia Howard$40$151.38 -73.1%Nov 24, 2023
Morgan StanleyDara Mohsenian$174$146.26 +17.1%Oct 18, 2023
Raymond JamesOlivia Tong$170$150.25 +14.4%Jan 13, 2023
J.P. MorganAnalyst unavailable$150$149.86 +0.9%Jan 13, 2023
Wells FargoAnalyst unavailable$168$150.62 +13.0%Jan 3, 2023
Deutsche BankAnalyst unavailable$162$148.47 +9.0%Dec 6, 2022
Wells FargoAnalyst unavailable$155$140.49 +4.3%Nov 16, 2022
Credit SuisseAnalyst unavailable$130$141.66 -12.5%Nov 15, 2022
Raymond JamesOlivia Tong$155$124.43 +4.3%Oct 12, 2022
Goldman SachsJason English$143$124.27 -3.8%Oct 9, 2022
Wells FargoAnalyst unavailable$150$126.25 +0.9%Oct 3, 2022
BarclaysLauren Lieberman$154$149.81 +3.6%Aug 18, 2022
Truist FinancialAnalyst unavailable$160$142.6 +7.6%Aug 1, 2022
J.P. MorganAnalyst unavailable$156$139.77 +5.0%Jul 21, 2022
Deutsche BankAnalyst unavailable$157$135.81 +5.6%Jun 21, 2022
Deutsche BankSteve Powers$171$132.36 +15.1%Jun 19, 2022
Wells FargoChris Carey$170$145.46 +14.4%Jun 6, 2022
BarclaysAnalyst unavailable$157$141.79 +5.6%May 23, 2022
Credit SuisseKaumil Gajrawala$150$161.74 +0.9%Apr 26, 2022
BarclaysAnalyst unavailable$176$161.39 +18.4%Apr 22, 2022
Deutsche BankAnalyst unavailable$177$164.54 +19.1%Apr 21, 2022
Raymond JamesAnalyst unavailable$180$163.65 +21.1%Apr 21, 2022
UBSPeter Grom$160$158.52 +7.6%Apr 19, 2022
Raymond JamesOlivia Tong$175$159.49 +17.7%Apr 11, 2022
Goldman SachsJason English$173$155.09 +16.4%Apr 1, 2022
Truist FinancialBill Chappell$175$150.82 +17.7%Mar 23, 2022
UBSPeter Grom$163$162 +9.7%Jan 20, 2022
Morgan StanleyDara Mohsenian$177$162 +19.1%Jan 20, 2022
Stifel NicolausMark Astrachan$148$161.13 -0.4%Jan 19, 2022
JefferiesKevin Grundy$187$161.13 +25.8%Jan 19, 2022
Wells FargoChristopher Carey$180$163.33 +21.1%Jan 5, 2022
Bank of America SecuritiesBryan Spillane$160$137.73 +7.6%Oct 5, 2021
Independent ResearchLars Lusebrink$154$140.79 +3.6%Aug 4, 2021
Credit SuisseKaumil Gajrawala$145$140.25 -2.4%Aug 2, 2021
DZ BANK AGMichael Pohn$119$133.58 -19.9%Apr 21, 2021
Show less

Track every rating change on PG the moment it posts. Free to start.

Start free

Market reaction

prior-close to event-session close
Stock move +1.7% Event window
SPY move +0.8% Same window
Abnormal move +0.9% Stock minus SPY
Volume 1.6× Versus trailing sessions
Subsequent drift -2.5% Up to 20 sessions
PGSPY benchmark

Follow PG with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Compared to Q2 FY26, described as the softest quarter due to inventory and trade headwinds, Q3 showed improvement with broad-based organic growth across every category and region. The $1 billion after-tax cost headwind was newly quantified this quarter, attributed to Middle East geopolitical disruption affecting commodity, energy, and logistics costs. Management introduced specific restructuring details: a 15% non-manufacturing headcount reduction target over two years and Supply Chain 3.0 automation rollout across nine categories. Innovation emphasis shifted toward home care (Dawn Powerwash, Fairy Skip the Soak, Mr. Clean) and beauty (SK-II, Pantene), whereas Q2 emphasized baby care (Pampers Prestige) and laundry (Tide Evo, Downy Intense). FY26 guidance was maintained in both quarters, but Q3 added the caveat that EPS is expected toward the lower end of the range, a subtle but meaningful shift in tone.

Guidance delta

FY26 guidance was maintained for the second consecutive quarter: organic sales growth of approximately +4%, core EPS of $6.83-$7.09, free-cash-flow productivity of 85-90%, and $15 billion in total cash returns to shareholders. The key delta is that management now expects full-year EPS to land toward the lower end of the range, reflecting the approximately $1 billion after-tax cost pressure from commodities, energy, and logistics. The 3% dividend increase and share repurchase program remain unchanged. Capex outlook continues to be increasing, consistent with the prior quarter's $10 billion capacity-investment plan.

Key takeaways

  • EPS of $1.59 beat the $1.56 estimate by 1.9%; revenue of $21.24B beat the $20.53B estimate by 3.4%.
  • Organic sales grew over 3% YoY with all ten categories and all seven regions posting growth.
  • Approximately $1 billion in after-tax cost headwinds from commodity, energy, and logistics pressures linked to Middle East conflict were quantified.
  • FY26 guidance was maintained, but full-year EPS is now expected toward the lower end of the $6.83-$7.09 range.
  • Dividend increased 3% and the $15 billion cash return plan remains unchanged.
  • Management flagged a 15% non-manufacturing headcount reduction target over two years alongside Supply Chain 3.0 automation across nine categories.

Management priorities

  • Scale up innovation pipeline across Baby Care (US), Tide Evo, and Pantene (Germany)
  • Roll out Supply Chain 3.0 automation technologies globally across nine categories
  • Invest in integrated data and AI tools for faster consumer-driven product development
  • Continue capacity additions in key categories under the $10 billion capex plan
  • Maintain dividend growth and share repurchase program targeting $15 billion in cash returns for FY26
  • Execute the 15% non-manufacturing headcount reduction over two years

Related earnings events

Consumer Defensive

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-28T09:11:19.274761+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T09:11:19.271950+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.